Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exert multiple effects relevant to CKD progression, including reductions in blood pressure, systemic inflammation, and albuminuria, as well as clinically meaningful weight loss
These findings suggest that the effects of SGLT2 inhibitors extend beyond hemodynamic improvements, involving direct modulation of intracellular pathways implicated in kidney injury
And so those are all components that needed to happen in order for that bigger vision to really come through. Gov
How GLP-1 Medications Improve Insulin Sensitivity GLP-1 receptor agonists like semaglutide activate receptors on insulin-producing cells in your pancreas, triggering the release of insulin only when blood sugar actually rises
Instead, doctors who treat obesity, and the serious health risks that come with it, fear the medications are making this health disparity worse
I am so happy we have access to this com